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Abstract
Background: CAH patients have an increased risk of cardiovascular disease, and it remains unknown if lifelong
glucocorticoid (GC) treatment is a contributing factor. In the general population, glucocorticoid receptor gene (NR3C1)
polymorphisms are associated with an adverse metabolic profile. Our aim was to analyze the association between the
NR3C1 polymorphisms and the metabolic profile of CAH patients.
Methodology: Sixty-eight adult patients (34SV/34SW) with a mean age of 28.469 years received dexamethasone (mean
0.2760.11 mg/day) to obtain normal androgen levels. SW patients also received fludrocortisone (50 mg/day). Metabolic
syndrome (MetS) was defined by the NCEP ATPIII criteria and obesity by BMI$30 kg/m2. NR3C1 alleles were genotyped, and
association analyses with phenotype were carried out with Chi-square, t-test and regression analysis.
Results: Obesity and MetS were observed in 23.5% and 7.3% of patients, respectively, and were not correlated with GC
doses and treatment duration. BMI was positively correlated with blood pressure (BP), triglycerides (TG), LDL-c levels and
HOMA-IR and inversely correlated with HDL-c levels. BclI and A3669G variants were found in 26.4% and 9.6% of alleles,
respectively. Heterozygotes for the BclI polymorphism presented with higher BMI (29 kg/m265.3 vs. 26 kg/m265.3,
respectively) and waist circumference (89 cm612.7 vs. 81 cm613, respectively) compared to wild-type subjects.
Hypertension was found in 12% of patients and heterozygotes for the BclI polymorphism presented higher systolic BP
than wild type subjects. Low HDL-c and high TG levels were identified in 30% and 10% of patients, respectively, and were
not associated with the NR3C1 polymorphisms. A3669G carriers and non-carriers did not differ.
Conclusion: In addition to GC therapy, the BclI GR variant might play an important role in obesity susceptibility in CAH
patients. Genotyping of GR polymorphisms could result in the identification of a subgroup at risk patients, allowing for the
establishment of personalized treatment and the avoidance of long-term adverse consequences.
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Introduction
Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase
deficiency is a common autosomal recessive disorder that leads to
decreased glucocorticoid secretion, with or without mineralocor-
ticoid deficiency, and to increased androgen production [1]. CAH
is caused by mutations in the CYP21A2 gene, which codes for 21-
hydroxylase, a key enzyme involved in cortisol and aldosterone
synthesis, and accounts for 90–95% of adrenal enzymatic defects
[1,2].
The spectrum of clinical manifestations depends on the degree
of 21-hydroxylase impairment, including a severe form with
prenatal virilization of the external genitalia in female fetuses and
postnatal virilization in both sexes, with or without salt loss
(classical forms), and a milder form with late onset hyperandro-
genic signs (nonclassical). The classical form of CAH has a
prevalence of about one in 15,000 to one in 16,000 live births in
the general population [1,2].
The introduction of glucocorticoid (GC) replacement therapy in
the 1950s has allowed for a normal life span in CAH patients.
Current GC therapy aims to provide adequate glucocorticoid
replacement dose and to suppress the abnormal androgen
secretion; mineralocorticoid replacement aims to control the renal
salt balance to avoid adrenal crisis [1,2,3]. Nevertheless, these
therapeutic goals are difficult to achieve in practice due to the
complexity of replicating the physiologic circadian rhythm of
cortisol secretion [4,5].
Recent studies have demonstrated the increased prevalence of
obesity, insulin resistance and hypertension [6,7,8], as well as
adverse lipid profiles, among adult and pediatric CAH patients.
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These findings suggest that CAH patients are prone to developing
an unfavorable cardiovascular risk profile [7]. CAH patients can
also develop signs and symptoms of iatrogenic Cushing’s syndrome
[3], mainly due to the supraphysiological doses of GC used to
suppress hyperandrogenism and chronically to reduce 17-hy-
droxyprogesterone (17-OHP) levels. Previous studies have associ-
ated the increased prevalence of obesity and hypertension with
hypercortisolism [9]; however, other factors may be involved, such
as individual glucocorticoid sensitivity.
Vo¨lkl et al. [10] demonstrated an important contribution of
parental obesity to the increased body mass index (BMI) in
children and adolescents with CAH, suggesting that genetic factors
could be involved with obesity predisposition. On the other hand,
none of the available studies have evaluated the role of genetic
polymorphisms on the metabolic profiles of CAH patients.
In the general population, some glucocorticoid receptor
(NR3C1) gene polymorphisms, are linked with increased BMI,
blood pressure and lipid levels and, consequently, increased
cardiovascular risk [11]. The BclI polymorphism, located at intron
2, has been associated with increased GC sensitivity and with these
abovementioned clinical manifestations [11,12,13,14,15]. Another
NR3C1 polymorphism, the A3669G, is linked with increased
expression and stabilization of the dominant negative splice
variant GR-b, which results in relative GC resistance. Recent
studies have suggested that A3669G carriers have an increased
pro-inflammatory state and an increased risk for cardiovascular
disease [11,16].
Considering the variability in the prevalence of obesity and
metabolic syndrome (MetS) in adult CAH patients, our aim was to
evaluate whether NR3C1 polymorphisms could account for the
development of this adverse metabolic profile in a series of CAH
patients from same center. We observed that BclI allele could
influence the sensitivity to glucocorticoids in CAH patients, since
their carriers presented higher BMI, waist circumference and
systolic blood pressure in comparison with non-carriers.
Methods
Subjects
The study was approved by the Ethical Committee of
Faculdade de Medicina da Universidade de Sa˜o Paulo (0231/
2010), and written consent was obtained from all the participants.
The inclusion criteria were patients with the classical form of
CAH, stable glucocorticoid and mineralocorticoid therapy in the
last two years, no use of enzyme inductor drugs and good
compliance, which was characterized by normal androgen and
PRA levels in at least 3 out of 4 annual measurements.
From a cohort of 135 adult CAH patients, we selected 68 with a
mean age of 28.468.6 years, who presented regularly at our
endocrine service. Thirty-four patients (24 females) had the simple
virilizing (SV) form, characterized by ambiguous genitalia in girls
and postnatal virilization signs in both sexes. Thirty-four patients
(24 females) had the salt wasting (SW) form, and they also
presented with volume depletion, sodium levels ,130 mmol/liter
and increased plasma renin activity (PRA). All patients presented
with a basal 17-OHP .150 nmol/L and molecular diagnosis of
classical CAH [17].
After reaching their final height, all individuals were treated
with dexamethasone (0.2760.11 mg) once a day, doses of which
are available in tablet (0.5 mg) and elixir (0.1 mg/mL) formula-
tions. Mean daily glucocorticoid doses were calculated by body
surface area (mg/m2) and evaluated retrospectively in the last 2
years. The glucocorticoid doses were converted to hydrocortisone
equivalents using anti-inflammatory equivalents (30 mg hydro-
cortisone= 0.75 mg dexamethasone). The hydrocortisone equiva-
lents are also presented as mg/m2. For the salt wasters,
fludrocortisone was maintained at a mean dose of 50625 mcg/
day. The mean of duration of glucocorticoid therapy was
25.469.8 years.
Hormonal Control
Treatment efficacy was assessed by hormonal control, charac-
terized by normal androgen levels according to sex. The
laboratory goals included the normalization of androstenedione
and testosterone levels for females during the follicular phase of
their menstrual cycle and androstenedione levels for men. The
mineralocorticoid replacement was monitored by blood pressure
and PRA, which was maintained in the upper half of the normal
reference range [18].
PRA was measured using commercial kits (CIS-Bio Interna-
tional Gif-Sur-Yvette, France). Serum androstenedione levels were
measured by chemiluminescence assay (Immulite 2000, Siemens
Health Care, UK). Intra-assay and inter-assay coefficients of
variation varied from 5% to 10%, respectively. Glucose was
determined by an automatic enzymatic colorimetric method using
hexokinase (Cobas Integra; Roche, Basel, Switzerland). Serum
testosterone and insulin was determined by Auto Delfia fluor-
oimmunoassay (Perkin-Elmer, Turku, Finland). Total cholesterol
(TC), high-density lipoprotein (HDL-c), low-density lipoprotein
(LDL-c) and triglycerides (TG) levels were analyzed by an
automatic enzymatic colorimetric method (Cobas Mira; F.
Hoffmann-La Roche, Basel, Switzerland).
Clinical, anthropometric and laboratory measurements
All patients underwent physical examination to obtain anthro-
pometric measurements. Obesity was defined by a BMI $30 kg/
m2 and overweight by a BMI between 25–29.9 kg/m2. Waist
circumference was defined as abnormal if $102 cm in men and
$88 cm in women.
Metabolic syndrome was defined according to the National
Cholesterol Education Program, Adult Treatment Panel III
criteria (NCEP ATPIII), with abnormal values for at least 3 of
the 5 criteria: waist circumference, systolic or diastolic blood
pressure, fasting glucose, HDL-c and triglycerides [19].
To evaluate the metabolic profile, blood samples were taken for
the measurements of glucose, insulin, TC, HDL-c, LDL-c and TG
at a fasting state, before the subjects took their hormonal
replacement therapy.
Elevated blood pressure was defined as values $135/
85 mmHg. Abnormal TG levels were characterized as values
$150 mg/dL, HDL-c ,40 mg/dL in men and ,50 mg/dL in
women and fasting glucose $110 mg/dL [19]. Insulin resistance
was assessed by the homeostasis model assessment for insulin
resistance (HOMA-IR).
Genetic Analysis
DNA samples from the patients were obtained from peripheral
blood leukocytes by salting out procedures. PCR amplification of
the glucocorticoid receptor gene regions was carried out using
primer sequences and amplification conditions as previously
described [20,21].
The A3669G polymorphism is located in the 39 untranslated
region of exon 9b, at nucleotide position 3669 (an A to G
alteration), and was genotyped by sequencing. PCR products were
sequenced using the Big Dye Terminator Sequencing KitTM
(Applied Biosystem, Inc., Foster City, CA, USA) and capillary
electrophoresis on an ABI PRISM 3100 sequencer (Applied
Biosystem, Inc.).
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The ER22/23EK polymorphism comprises two linked, single
nucleotide variations separated by one base pair in exon 2. The
first substitution at nucleotide position 198 is silent, changing
codon 22 from GAG to GAA. The second mutation changes
codon 23 at nucleotide position 200 from AGG to AAG. The
N363S polymorphism changes codon 363 of exon 2 at nucleotide
position 1220 from AAT to AGT. Sequence traces were analyzed
using Sequencher (version 4.5 build 1416).
The BclI polymorphism results in an intronic C to G change,
646 nucleotides downstream from exon 2. It was screened by an
allele-specific PCR as previously described [21]. The results of the
allele-specific PCR were confirmed by direct sequencing in 20
patients.
Statistical analysis
Comparison of genotypes frequencies between different groups
of patients and sex was carried out using a x2 test. Normal
distribution for all continuous variables was tested, and some were
logarithmically transformed. At baseline, independent t-test for
independent groups was applied to compare continuous variables.
Results are reported as means 6 SD. These analyses were also
performed with adjustment for age and sex by multivariable
modeling.
Pearson’s correlation coefficients were used to calculate
correlations between BMI, GC dose, insulin, HOMA, and lipid
levels after correction for age and sex. Correlation analysis was
also applied to compare the mean androgen levels of the least two
years of GC therapy with BMI, waist circumference, BP and
metabolic profile. P,0.05 was considered to indicate a significant
difference.
Hardy–Weinberg equilibrium for the BclI and A3669G variants
was calculated. Statistical analysis was performed using the
software SigmaStat version 3.5 for Windows (Systat Software,
Point Richmond, CA).
Results
The clinical and anthropometric data of CAH patients are
described in Table 1. Allelic frequencies of BclI and A3669G
NR3C1 polymorphisms were in Hardy-Weinberg equilibrium. The
BclI polymorphism was found in 26.4% of the alleles, with 6
homozygous patients and 24 heterozygous patients. The A3669G
polymorphism was found in 9.6% of the alleles, in 11 heterozygous
patients and only 1 homozygous patient. The N363S and ER22/
23EK alleles were identified in 1 patient as heterozygous for each
polymorphism. For statistical analysis, we selected only polymor-
phisms with a frequency $5% (BclI and A3669G).
Obesity and metabolic syndrome prevalence in adults
with CAH
Obesity was observed in 16 CAH patients (23.5% of patients),
being more prevalent in the males (n = 9, 56%), and in similar
frequencies between the SW and SV groups (50%). Overweight
was observed in 23 patients (33.8% of patients), and it was more
frequent in the patients with the SW form (n= 13, 56.5%) and in
females (n = 18, 78.3%). Metabolic syndrome was observed in
7.3% of patients; three out of 5 patients presented with the simple
virilizing form, and 3 were male.
Clinical and biochemical markers of metabolic risk
BMI was positively correlated with higher systolic and diastolic
blood pressures, triglycerides, LDL-c levels and HOMA-IR values
(P,0.01), and it was inversely correlated with HDL-c levels
(P=0.03). There were no correlations among BMI, GC dose,
duration of therapy and androstenedione and testosterone levels,
although the latter measurements were inversely correlated with
HDL-c levels in female patients (testosterone r =20.45, P,0.01;
androstenedione r =20.629, P,0.01). The remaining compo-
nents of MetS were not correlated with androstenedione levels in
both sexes.
As expected, the male patients presented with worse metabolic
profiles compared to the females, characterized by increased WC
values, higher BMI, systolic blood pressure, LDL-c and TG levels
and lower HDL-c levels (Table 1). Increased TG levels
($150 mg/dL) were observed in 10% of the patients (n = 7), with
4 out 7 patients presenting with the SV form. Low HDL-c levels
were observed in 19 patients (30% of cases), with higher frequency
in the SW form compared to the SV form (n= 12, 63%).
Hypertension was identified in 8 patients (12%) and was more
prevalent in the SV patients (n = 5, 71.4%). Increased waist
circumference values were observed in 14 patients, being more
prevalent in the SV patients (n = 9, 64%) and with similar
frequencies between both sexes (n = 7 both, 50%).
Decreased serum HDL-c levels were the most frequent
component of the metabolic syndrome (30%) identified, followed
by increased waist circumference (23.5%), high blood pressure
(12%) and serum triglycerides levels (10%). Fasting plasma glucose
level higher than 110 mg/dL was not observed in this series. The
frequencies of the metabolic syndrome components, such as
increased TG levels and blood pressure, were higher in the obese
patients compared to the non-obese patients (Figure 1, P,0.05),
independent of sex, age, GC dose, clinical form and duration of
treatment.
Impact of NR3C1 polymorphisms on the metabolic
profile of CAH patients
Comparison of the clinical and laboratory data between carriers
and non-carriers of the BclI polymorphism is shown in Table 2.
BclI carriers presented with higher BMI, waist circumference and
systolic blood pressure compared to wild-type carriers in the t-test
analysis. These results were also adjusted according to sex and age
in the linear multiple analyses and remained statistically significant
(Table 2). We also found that BclI heterozygous carriers also
presented higher BMI (29 kg/m265.3 vs. 23.9 kg/m262.7,
P=0.03), waist circumference (89 cm612.7 vs. 72.8 cm65.6,
P=0.005) and TG levels (91.3 mg/dL645.5 vs. 50.7 mg/
dL627.8, P=0.009) as compared to BclI homozygous carriers.
There were no significant differences observed in the HOMA-IR
value and lipid profile between carriers and non-carriers of the BclI
polymorphism (Table 2).
The frequency of the BclI polymorphism was higher in the obese
patients compared to the non-obese patients (62.5% vs. 38.4%,
respectively), and the frequency was also higher in the patients
presenting with the metabolic syndrome (80% vs. 41.3%,
respectively); however, these differences were not statistically
significant.
Table 3 shows the clinical and laboratorial data of A3669G and
wild-type carriers, and no differences were identified in cardio-
vascular risk factors such as BMI, waist circumference, blood
pressure, HOMA-IR and lipid profile. There was no significant
difference in the frequency of the A3669G polymorphism between
the obese and non-obese CAH patients, 12.5% vs. 19.2%,
respectively, or between the patients with and without metabolic
syndrome, 20% vs. 17.4%, respectively.
GR Polymorphisms and Metabolic Profile of CAH
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Discussion
The introduction of glucocorticoid therapy 60 years ago has
allowed for a normal life span to CAH patients; however,
increasing attention has been paid to the adverse long-term health
effects of chronic hyperandrogenism and/or glucocorticoid
therapy on the metabolic profile [7,8,22]. There is evidence of
the increased prevalence of overweight/obesity in CAH patients
compared to the normal population [6,7,23], and there is debate
on whether long-term GC exposure or higher GC doses might be
contributing factors.
In a multicenter study from the United Kingdom, a higher
prevalence of obesity was observed in CAH patients (41% of
patients) in comparison with the reference population. However,
these patients received different regimes of glucocorticoids and
suppressed 17-OHP levels (,12 nmol/L) were observed in 45%
and 37% of CAH females and males, respectively [6]; thus, over-
treatment could contribute to the development of obesity.
Although in our series we selected patients followed in a same
center and under a homogenous glucocorticoid replacement and
hormonal control, we also found a higher frequency of obesity in
comparison with our reference population (25), but it was lower
than the former study (7). The aim of GC substitution therapy in
our series was just to normalize the androgen levels, but not 17-
OHP, and therefore the mean 17-OHP levels were higher
(175.2 nmol/L) than the United Kingdom series and probably
the mean daily GC doses could be lower in our patients.
Considering these findings, we also speculated whether GC doses
and/or duration of therapy differed between the obese and non-
obese CAH patients and no significant differences were observed.
According to the MetS prevalence in our cohort, it was similar
to the reference population from the same region [24]. Other
CAH studies presented discordant results, and thus, we could not
rule out an effect of different sample sizes, GC regimes and aims in
the hormonal control as well as the use of different criteria in
defining cardiovascular risk factors [6,25,26]. As it occurs in the
general population, several factors could be involved with
cardiovascular risk in CAH patients, such as obesity, hypertension
and familial and/or genetic predisposition. Many works have
analyzed the role of the BclI and A3669G NR3C1 polymorphisms
Table 1. Clinical and anthropometric characteristics of 68 adult CAH patients.
Variables Female (N=48) Male (N=20) P value
Age, mean [SD], years 29.2 (9.5) 26.9 (6.8) 0.449
BMI, mean [SD], kg/m2 25.7 (4.1) 29.5 (7.1) 0.035
Increased WC, n (%) 7 (14.6) 7 (35) 0.238
GC dose, mean [SD], mg/m2 11.2 (4.5) 10.5 (3.7) 0.696
Duration of GC therapy, years 26.6 (10.6) 21.9 (7.2) 0.039
HOMA-IR index, mean [SD] 2.24 (1.02) 2.5 (1.7) 0.376
Total cholesterol, mean [SD], mg/dL 174 (35) 186.3 (33.3) 0.186
HDL-c, mean [SD], mg/dL 58.2 (13.2) 49 (12) 0.010
LDL-c, mean [SD], mg/dL 100.2 (28) 116.8 (26.9) 0.033
Triglycerides, mean [SD], mg/dL 78.4 (40.5) 102.7 (45.8) 0.014
Systolic blood pressure, mean [SD], mmHg 118.7 (18.9) 123.5 (8.3) 0.042
Diastolic blood pressure, mean [SD], mmHg 76.9 (6.7) 80.1 (6.8) 0.074
Values are given as means 6 SD. BMI: Body Mass Index; GC, glucocorticoid; WC: Waist Circumference.
doi:10.1371/journal.pone.0044893.t001
Figure 1. Comparison of frequency of metabolic syndrome components between CAH obese and CAH non-obese patients
according to NCEP ATPIII criteria.
doi:10.1371/journal.pone.0044893.g001
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Table 2. Impact of BclI polymorphism on the metabolic profile of CAH patients.
Genotypes
Variable
BclI (homozygous)
n =6
BclI (heterozygous)
n =24
Wild type
n=38 P valuea,b
Adjustedb
P value
Confidenceb Interval
CI 95%
BMI, mean [SD], kg/m2 23.9 (2.7) 29 (5.3) 26 (5.3) 0.018 0.044 1.00–1.24
Waist circumference,
mean [SD], cm
72.8 (5.6) 89 (12.7) 81 (13) 0.011 0.044 1.00–1.09
GC dose, mean [SD],
mg/m2
11.2 (4.4) 9.9 (3.7) 11.6 (4.6) 0.137 0.164 0.78–1.04
Duration of GC therapy,
mean [SD], y
22 (5.5) 25.6 (9.5) 25.4 (10.8) 0.240 0.461 0.91–1.21
HOMA-IR index 2.3 (1.5) 2.3 (1.4) 2.4 (1.2) 0.452 0.854 0.62–1.47
Serum total cholesterol,
mean [SD], mg/dL
159.2 (27.2) 177 (39) 180.9 (32.8) 0.669 0.728 0.98–1.01
Serum HDL, mean [SD],
mg/dL
63 (15.5) 52 (14.4) 56.5 (12.2) 0.111 0.216 0.93–1.02
Serum LDL, mean [SD],
mg/dL
86 (19.6) 106.3 (30.6) 107.3 (27.8) 0.224 0.901 0.98–1.02
Serum triglycerides,
mean [SD], mg/dL
50.7 (27.8) 91.3 (45.5) 87.4 (42.2) 0.009 0.828 0.99–1.01
Systolic blood pressure,
mean [SD], mmHg
123 (6.7) 124.9 (7.1) 116.7 (8.9) ,0.001 0.008 1.03–1.29
Diastolic blood pressure,
mean [SD], mmHg
75.3 (5.6) 80.1 (7.1) 76.8 (6.5) 0.064 0.179 0.97–1.16
Values are given as means 6 SD.
Adjusted for age and sex.
aUnivariated analysis.
bComparison between BclI heterozygous and wild type carriers.
BMI: Body Mass Index; GC: glucocorticoid.
doi:10.1371/journal.pone.0044893.t002
Table 3. Impact of A3669G polymorphism on the metabolic profile of CAH patients.
Genotype
Variables A3669G n=12 Wild type n=56 P valuea Adjusted P value Confidence Interval - CI 95%
BMI, mean [SD], kg/m2 26.8 (5) 26.8 (5.5) 0.942 0.974 0.88–1.13
Waist circumference,
mean [SD], cm
83.3 (12.2) 83 (13.5) 0.797 0.997 0.95–1.05
GC dose, mean [SD], mg/m2 10.6 (5) 11.1 (4.2) 0.727 0.947 0.84–1.18
Duration of GC therapy,
mean [SD], y
22.8 (12.1) 25.6 (9.4) 0.631 0.621 0.85–1.05
HOMA-IR index, mean [SD] 2.1 (0.7) 2.4 (1.4) 0.427 0.594 0.47–1.54
Serum total cholesterol,
mean [SD], mg/dL
192.7 (24.4) 174.4 (35.9) 0.097 0.192 0.99–1.04
Serum HDL-c, mean [SD], mg/dL 58.8 (9.5) 54.8 (14.1) 0.346 0.370 0.97–1.08
Serum LDL-c, mean [SD], mg/dL 115.6 (28.1) 102.8 (28.3) 0.161 0.219 0.99–1.04
Serum triglycerides, mean [SD],
mg/dL
88.6 (35.1) 84.9 (45.1) 0.398 0.897 0.98–1.02
Systolic blood pressure,
mean [SD], mmHg
121.5 (13.2) 119.8 (7.9) 0.600 0.718 0.93–1.11
Diastolic blood pressure,
mean [SD], mmHg
78.5 (8) 77.7 (6.5) 0.708 0.974 0.89–1.11
Values are given as means 6 SD.
Adjusted for age and sex.
aUnivariated analysis.
doi:10.1371/journal.pone.0044893.t003
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on the cardiovascular risk in the general population. The BclI
polymorphism has been linked to increased GC sensitivity and
consequently to higher BMI, waist circumference and lipid levels,
compared to wild type carriers [11]; however, there are no data
about the impact of these NR3C1 polymorphisms on the metabolic
profile of CAH patients.
In this study, we tested the association analysis between NR3C1
polymorphisms and these traditional cardiovascular risk factors in
patients treated exclusively with dexamethasone and similar
hormonal control. Our results are consistent with previously
published data from the general population, because our CAH
patients carrying the BclI allele presented with increased BMI and
waist circumference, independent of sex and age (Table 2).
Additionally, the frequency of the BclI polymorphism was higher
in the obese CAH compared to the non-obese CAH, but without
statistical significance; thus, a sample size effect cannot be
excluded.
The BclI allele has been also associated with higher blood
pressure values and/or higher prevalence of hypertension [15] and
similarly our CAH patients carrying this allele also presented
higher systolic blood pressure levels. Probably, this result was not
directly influenced by the dexamethasone therapy, considering
that it has little mineralocorticoid effect [27]. Based on the data of
our statistical analysis, the BclI allele and BMI were the major
factors influencing the blood pressure values.
The fact that BclI heterozygous carriers presented with
increased BMI, waist circumference and systolic blood pressure
compared to two subgroups of homozygous carriers (mutant and
wild-type) is in line with the observation in a previous study in
which patients carrying the heterozygous BclI polymorphism
gained more than twice the subcutaneous adiposity compared to
homozygous subjects [28]. As hypothesized by Tremblay et al.
[28], this phenomenon can be explained by a possible linkage
disequilibrium between the BclI polymorphism and other
polymorphisms located at regulatory regions that could influence
the observed phenotype. Moreover, the compound heterozygosity
could modify the GR responses to glucocorticoid, which was not
observed in the homozygous carriers. This theory of the
heterozygous phenotype is supported by two animal models, in
which only the heterozygous and not the homozygous carriers
develop the expected phenotype [29,30]. However, it is important
to emphasize that few patients were homozygous for this variant in
our series and a sample size effect cannot be excluded.
Additionally, our results suggest that BclI CAH carriers might
need lower GC doses (Table 2); but probably due to sample size,
this result did not reach statistical significance. Supporting this
hypothesis, it was observed that, due to increased GC sensitivity
associated with the BclI polymorphism, patients with inflammatory
bowel disease carrying this variant present a better response to
glucocorticoid therapy [31].
The A3669G polymorphism is associated with increased
expression and stabilization of the 9b GR isoform, and it is
correlated with glucocorticoid resistance. A recent study suggested
the involvement of this polymorphism with the increased risk of
cardiovascular disease in carriers compared to non-carriers. This
hypothesis was supported by the findings of elevated levels of
inflammatory parameters, such as IL-6 and C reactive protein, in
a large cohort of elderly subjects [16]. Our CAH patients carrying
the A3669G polymorphism, although they present with similar
mean BMI, total cholesterol, LDL-c and triglycerides levels were
higher than compared to non-carriers. However, only 12 patients
carried this allele and this finding was not statistically significant
(Table 3).
Besides the genetic predisposition and glucocorticoid exposure,
other factors could predispose to an adverse metabolic profile in
CAH patients and as expected BMI presented significant influence
on HOMA-IR, lipid levels and blood pressure, which were
reinforced by the finding that obese CAH patients presented with
higher frequency of MetS components than the non-obese
patients. Another important factor is long-term hyperandrogenic
exposure, which might be an independent contributor to the
development of the metabolic syndrome’s components. In a cohort
of untreated female patients with the simple virilizing form was
observed lower insulin sensitivity and higher body weight, blood
pressure, and more metabolic disorders, including higher serum
TG, and lower HDL-c [22] than the controls. To exclude the
effects of increased androgens levels, we selected only patients with
adequate hormonal control, and interestingly, mean androgen
levels over the last 2 years of therapy were inversely correlated
with lower HDL-c levels in our female patients. Although these
patients presented normal androgen levels, glucocorticoid therapy
probably does not reproduce or allow a normal adrenal androgen
secretion.
The findings of our study suggest that the BclI polymorphism
could play an important role in the susceptibility for obesity and
higher systolic blood pressure in CAH patients and the positive
correlation between BclI polymorphisms and BMI also suggests
that the different sensitivities and individual responses to
glucocorticoids are at least partially genetically determined [32].
Hence, GR screening during the treatment of CAH patients could
help to improve the quality of GC replacement, by identifying
subgroup patients at-risk who would benefit the most from
personalized treatment. In these patients, we speculate that
attempts to reduce 17-OHP levels significantly could predispose
them to worse metabolic consequences, and we encourage the
application of preventive measures.
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